A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

Debra Patt, MD, PhD, MBA, MPH, warns that prior authorization barriers are delaying critical cancer treatments and urges a ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Clayton Irvine, PharmD, MBA, MS, senior manager of oncology care at Mayo Clinic, emphasizes the need for health care ...

Access and affordability are among the top priorities in health care for Americans who participated in the survey.

Women living in rural Appalachia who are at high-risk of HIV had effective interventions delivered through Facebook.

Panelists discuss how black box warnings on IV iron products, particularly regarding hypersensitivity reactions, influence their risk assessment, patient selection, monitoring protocols, and facility ...

Panelists discuss how hypophosphatemia can cause both acute effects like muscle weakness and confusion and chronic ...

On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

Abandoning efforts to reform payment for cell and gene therapies for Medicaid beneficiaries could allow ongoing access ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...